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Summary
We intended to evaluate the influence of sex mismatch between donor and recipi-
ent, which is still under much debate, on survival and comorbidities after cardiac
transplantation. From November 2003 to December 2013, a total of 258 patients
were transplanted in our center. From these, 200 receptors were male (77.5%)
and constituted our study population, further divided into those who received
the heart from a female donor (Group A) – 44 patients (22%) and those who
received it from a male donor (Group B) – 156 (78%). Median follow-up was
4.2  3.0 years (1–10 years). The two groups were quite comparable with each
other, except for body mass index, systolic pulmonary artery pressure, and trans-
pulmonary gradient, which were significantly lower in Group A. A low donor/
recipient weigh ratio (<0.8) was avoided whenever possible. Hospital mortality
was not different in the two groups. During follow-up, global survival was similar,
as was survival free from acute cellular rejection and cardiac allograft vasculopa-
thy. However, patients in Group A had decreased survival free from serious infec-
tions and malignant tumors. Allocation of female donors to male receptors can be
done safely, at least in receptors without pulmonary hypertension and when an
adequate donor/recipient weigh ratio is ensured.
Introduction
Heart transplantation remains the treatment of choice for
symptomatic terminal heart failure [1]. However, the long-
term results are still far from ideal, essentially characterized
by the morbidity and mortality caused by acute cellular
rejection and vascular graft disease, on the one hand, and
episodes of infection and neoplasia, on the other [2], and
influenced by many factors related to the characteristics of
both the recipient and donor.
Among these, the impact of the gender mismatch
between donor and recipient on patient survival and in
each of those morbidities is still under debate, with dispa-
rate results in different studies. While some consider the
simple fact of the donor being female as a risk factor for
survival [3], others found no difference in long-term mor-
tality whatever the sex of the donor or receptor [4].
Recently, Kush et al. [5] indicated sex mismatch between
donor and recipient, regardless of the sex of the recipient,
as a cause of increased long-term mortality. However, the
negative impact of the mismatch female donor to male reci-
pient seems more consensual.
Beyond pure survival analysis, few studies have been
devoted to the research of the influence of gender disparity
between donor and recipient on other morbidities such as
acute cellular rejection, vascular graft disease, infections,
and neoplasms. In this study, we intended to evaluate the
influence of gender disparity in male recipients, not only
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on survival but also on the incidence of those important
morbidities.
Patients and methods
From November 2003 to December 2013, a total of 258
patients were transplanted in our center. Of these, 200 male
recipients (77.5%) were selected for this study and were
divided into two groups: Group A – recipients receiving an
organ from a female donor, that is, with gender mismatch
– 44 patients (22%); and Group B – recipients from a male
donor, that is, with matching gender – 156 patients (78%).
All transplantations, including the respective organ
recovery, were performed by the same surgical team. The
technique used was the bi-caval anastomosis with modifica-
tions previously described with the aim of reducing the
duration of ischemia [6]. After transplantation, the imme-
diate and early postoperative period, the regular clinical fol-
low-up and treatment of various complications in the
medium and long term were also carried out at the center
by members of the surgical team, which includes an Inter-
nal Medicine specialist specifically dedicated to this activity.
Only exceptionally have we resorted to the assistance of
centers nearest to the residence of the patients. This is the
current case with four patients currently residing abroad,
from whom we also got the tracking data.
We had access to a pretransplant cross-match in all cases,
and have only transplanted patients in whom this was nega-
tive. Analysis of the panel-reactive antibody (PRA), which
is usually only known after transplantation and condi-
tioned the immunosuppression regimen, was also per-
formed in the majority of cases.
All patients received induction immunosuppression with
the antagonist of interleukin-2 receptor (basiliximab –
20 mg intravenously), methylprednisolone (500 mg iv),
and mycophenolate (1 g oral), immediately before and/or
during the intervention. In the majority of patients (97.7%
vs. 96.2%; P = 1.000), follow-up immunosuppression was
initiated with cyclosporine, dose-adjusted to serum levels,
mycophenolate mofetil (500–1000 mg tid, initiated before
surgery) and prednisone in decreasing doses from 0.8 mg/
kg initially to 10 mg/day after around 5 weeks, 7.5 mg/day
after 6 months and 5 mg/day after 1 year. Tacrolimus
instead of cyclosporine was reserved for younger patients,
or those already doing this drug for a kidney transplanta-
tion (2.3% vs. 3.2%; P = 1.000) [7].
Early mortality was defined as death occurring during
the hospitalization of surgery or within 30 days and late
mortality as that which occurred after this period. Endo-
myocardial biopsies were performed routinely by protocol
or when considered medically necessary. Acute cellular
rejection was diagnosed and treated if grade ≥2R of the
classification of the International Society for Heart and
Lung Transplantation (ISHLT) [8]. Each patient underwent
coronary angiography annually, with graft vascular disease
diagnosed using the criteria also defined by ISHLT [9]. For
the calculation of the freedom-survival curves, the defini-
tion of malignancies included malignant neoplasms of the
skin, blood, breast, gastrointestinal, prostate, or other. The
definition of infections included serious infectious compli-
cations, regardless of origin, which obliged to hospital
admission for intravenous antibiotics.
The pre-and postoperative clinical data, as well as infor-
mation for analysis of survival and incidence of adverse
long-term events were prospectively collected in a database
constructed in conjunction with our national society of
transplantation (Sociedade Portuguesa de Transplantac~ao –
SPT), which aims at collating all transplantation activity
country-wide. For this work, the data from this single cen-
ter were extracted.
Statistical analysis
Continuous variables are presented as mean  standard
deviation and compared between groups using the Stu-
dent’s t-test for normally distributed variables and Mann–
Whitney U-test for variables with non-normal distribution.
The normality of variables was evaluated by the Kolmogo-
rov–Smirmov and Shapiro–Wilk tests. Categorical variables
are expressed as frequencies and percentages and compari-
son was made using the chi-square test or, when appropri-
ate, Fisher’s exact test. Overall survival and group survival,
as well as event-free survivals, were assessed by the Kaplan–
Meier method, and statistical significance was analyzed
using the log-rank test. Values of P < 0.05 (two-tailed)
were considered statistically significant. Data were analyzed
using the IBM Corp. program (Released 2011, IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY: IBM
Corp).
Results
Table 1 documents the main demographic and preopera-
tive clinical characteristics of both groups of recipients. The
mean age of Group A was slightly higher (55.8 vs.
53.1 years) but without statistical significance (P = 0.196).
This group includes one patient (2.3%) under the age of
18, while in Group B there were 4 (2.6%; P = 1.000). The
body mass index was significantly lower in patients with
gender mismatch, and sPAP and transpulmonary gradient
were significantly lower, resulting from a deliberate move
to avoid the use of female donors in recipients with some
degree of pulmonary hypertension. Regarding the presence
of other comorbidities, both groups proved fairly homoge-
neous, with comparable incidence of diabetes, hyperten-
sion, dyslipidemia, peripheral vascular disease, or carotid
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artery disease. Also in the etiology of the underlying heart
disease, the prevalence of ischemic and dilated causes was
similar, as was the history of previous cardiac surgery. Two
patients (1.3%) in Group B and none in Group A
(P = 1.000) had previously been transplanted to other
organs (kidney and liver).
Donors in Group A were older than in Group B
(Table 2). We also found significant differences in the
cause of death of the donor. Hemorrhagic cerebral acci-
dents were more frequent in female donors, while the cra-
nio-cerebral injuries were more frequent in males.
Intraoperatively, a mitral valvuloplasty for previously
known mitral disease, which has been the subject of a previ-
ous publication [10], was performed in nine patients and
was more prevalent in the hearts from female donors. The
data in Table 3 shows that although the time of ischemia,
time to extubation, and the need for mechanical assistance
were similar, prolonged use of inotropic drugs (>48 h) was
more frequently required in Group A. Concurrent renal
transplantation was performed in one patient (2.3%) in
Group A and in three (1.9%) in Group B (P = 1.000). The
Table 1. Preoperative data of heart transplant recipients in the two
groups.
Recipient
Group A
(w/sex
mismatch) (%
or mean  SD)
Group B
(w/o sex
mismatch) (%
or mean  SD) P
n 44 (22) 156 (78)
Recipient age
(years)
55.8  11.3 53.1  12.3 0.196
BMI mean (kg/m2) 22.9  2.3 24.4  3.5 0.001
Diabetes 45 (28.8) 9 (20.5) 0.268
Essential hypertension 17 (38.6) 60 (38.5) 0.983
Dyslipidemia 21 (47.7) 84 (53.8) 0.473
Prior cardiac surgery 14 (31.8) 46 (29.5) 0.766
Prior CABG 6 (13.6) 30 (19.2) 0.394
Ischemic cardiomyopathy 18 (40.9) 70 (44.9) 0.640
Dilated cardiomyopathy 11 (25.0) 43 (27.6) 0.735
Peripheral vascular disease 19 (43.2) 60 (38.5) 0.572
Carotid stenosis 3 (6.8) 9 (5.8) 0.729
Cardiac index (l/min/m2) 1.95  0.56 1.99  0.48 0.672
Systolic pulmonary
artery pressure
44.6  14.5 51.0  15.2 0.017
Trans-pulmonary
gradient (mmHg)
8.32  3.47 10.45  4.99 0.002
Pulmonary vascular
resistance (UW)
3.07  2.80 3.35  1.91 0.469
VO2 max (ml/kg/min) 13.8  2.6 13.4  2.9 0.436
Bilirubin (mg/dl) 1.4  0.9 1.3  0.9 0.692
Glomerular filtration
rate (ml/min)
57.4  23.3 63.1  23.2 0.171
Creatinine level (mg/dl) 1.7  1.0 1.5  0.7 0.271
Wait-list time (days) 39.8  41.6 46.3  44.6 0.388
Follow-up (years) 4.35  3.34 4.21  2.95 0.793
High urgency classification 14 (31.8) 45 (28.8) 0.703
BMI, body mass index; CABG, coronary artery bypass grafting;
VO2 max, maximal oxygen consumption.
P values in bold are those considered significative.
Table 2. Characteristics of the donors.
Donor
Group A
(female
donor) (% or
mean  SD)
Group B
(male
donor) (% or
mean  SD) P
n 44 (22) 156 (78)
Age (years) 37.9  9.1 34.3  11.5 0.032
PRA (%) 0.2  1.2 1.1  4.2 0.302
Ratio weight
donor/recipient
1.05  0.21 1.15  0.29 0.030
Ratio weight donor/
recipient <0.8
1 (2.3) 5 (3.2) 1.000
Ratio weight donor/
recipient >1.2
8 (18.2) 48 (31.2) 0.092
Inotropic
dependence >1 week
3 (6.8) 8 (5.1) 0.709
Ventilator
assistance >1 week
6 (13.6) 20 (12.8) 0.887
Cause of death
Ischemic cerebral
accident
0 (0) 3 (1.9) 1.000
Hemorrhagic cerebral
accident
25 (56.8) 41 (26.3) <0.001
Brain trauma 12 (27.3) 102 (65.4) <0.001
PRA, panel-reactive antibodies.
P values in bold are those considered significative.
Table 3. Operative and postoperative data.
Surgery
Group A
(w/sex
mismatch) (% or
mean  SD)
Group B
(w/o sex
mismatch) (% or
mean  SD) P
Total ischemic time (min) 96.9  33.2 87.9  37.7 0.127
CPB time mean (min) 96.8  29.4 97.3  28.8 0.923
Mitral valvuloplasty 6 (13.6) 3 (1.9) 0.004
Time to extubation (h) 18.4  9.0 20.6  26.8 0.587
Inotropic requirement 10 (22.7) 16 (10.3) 0.030
Mechanical assistance 1 (2.3) 6 (3.8) 1.000
Hemorrhage 6 (13.6) 7 (4.5) 0.041
Length of hospital
stay (days)
21.5  28.7 14.8  10.8 0.144
Hospital mortality 1 (2.3) 8 (5.1) 0.687
Immunosuppression
Cyclosporine ab initio 43 (97.7) 150 (96.2) 1.000
Calcineurin inhibitor
change
7 (15.9) 17 (10.9) 0.366
MMF to everolimus
change
6 (13.6) 33 (21.2) 0.266
MMF to sirolimus
change
1 (2.3) 2 (1.3) 0.527
CPB, cardiopulmonary bypass; MMF, mycophenolate mofetil.
P values in bold are those considered significative.
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hospital stay was, on average, longer in the group with mis-
match, but without statistical significance. Finally, the mor-
tality rate was lower in Group A (2.3% vs. 5.1%), although
this difference did not reach statistical significance
(P = 0.687). The incidence of acute cellular rejection grade
1R during the first 3 months post-transplantation was mar-
ginally but not significantly higher in Group A (40.9% vs.
31.4%; P = 0.238).
There was a need to change the calcineurin inhibitor in
15.9% vs. 10.9% (P = 0.366), mainly due to renal, infec-
tious or neoplastic complications, humoral and/or cellular
rejection, convulsions, and allograft vasculopathy. The need
to change from mycophenolate mofetil to everolimus
(13.6% vs. 21.2%; P = 0.266) and sirolimus (2.3% vs.
1.3%; P = 0.527) was related to the development of graft
vascular disease.
For a mean follow-up period of more than 4 years and a
maximum of 10 in both groups (Table 1), with regard to
the long-term adverse events, we found an overlapping
incidence of humoral rejection between groups A and B
(2.3% vs. 2.6%, P = 1.000). The incidence of new onset
diabetes after transplantation (NODAT) was slightly
higher, but with no statistical significance, in the group
without mismatch (11.4% vs. 15.4%; P = 0.503). There was
worsening renal function, requiring permanent dialysis or
kidney transplantation during follow-up, in three cases in
Group A (6.8%) and four in Group B (2.6%, P = 0.181).
The overall mortality of Group A and B was 27.3% and
21.8% (P = 0.446), respectively. There were no marked dif-
ferences in the incidence of major causes of death (cardiac,
infectious, vascular, neoplastic, and neuropsychiatric;
Table 4). Overall survival at 1, 5, and 8 years was
86.1  5.3%, 71.0  7.6%, and 66.6  8.3%, respectively,
in Group A and 87.5  2.7%, 77.7  3.7%, and
71.6  4.9% for Group B. There was, therefore, no signifi-
cant difference in survival between the two groups
(P = 0.529; Fig. 1).
During the first year of follow-up, acute cellular rejection
grade 2R or 3R occurred in nine cases (20.5%) in recipients
with gender mismatch and in 23 (14.7%) in the group
without mismatch (P = 0.361). Survival free from this type
Table 4. Global mortality and causes of death.
Mortality
Group A
(w/sex
mismatch) (%)
Group B
(w/o sex
mismatch) (%) P
Global mortality 12 (27.3) 34 (21.8) 0.446
Cause of death
Cardiac 2 (4.5) 6 (3.8) 1.000
Vascular 3 (6.8) 7 (4.5) 0.461
Ischemic cerebral
accident
1 (2.3) 2 (1.3) 0.527
Hemorrhagic
cerebral accident
1 (2.3) 2 (1.3) 0.527
Acute mesenteric
ischemia
1 (2.3) 1 (0.6) 0.392
Pulmonary
hypertension
0 (0.0) 2 (1.3) 1.000
Malignant tumor 0 (0.0) 8 (5.1) 0.204
Neuropsychiatric 0 (0.0) 2 (1.3) 1.000
Infectious 4 (9.1) 8 (5.1) 0.303
Figure 1 Overall survival in groups A and B.
Figure 2 Survival free from acute cellular rejection grade ≥2R in groups
A and B.
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of rejection at 1, 5, and 8 years was 76.8  6.8%,
73.8  7.2%, and 73.8  7.2%, respectively, in Group A
and 84.0  3.1%, 82.3  3.2%, and 77.1  4.9% for
Group B. As one would expect and can be seen in Fig. 2,
the incidence of cellular rejection was most pronounced in
the first 2 years. Although survival free from acute cellular
rejection was slightly better in Group B, the difference did
not reach statistical significance (P = 0.453).
Survival free from graft vascular disease at 1, 5, and
8 years was 97.1  2.9%, 87.8  6.9%, and 87.8  6.9%,
respectively, in Group A and 97.6  1.4%, 87.2  3.6%,
and 72.8  6.4% for Group B (P = 0.299). In this case, the
survival curve (Fig. 3a) is very similar during the first
5 years, and from then onwards the group with gender mis-
match seems to have a better disease-free survival of the
graft.
Malignancy-free survival at 1, 5, and 8 years was, respec-
tively, 97.7  2.3%, 78.1  8.2%, and 55.5  11.2% in
Group A and 97.8  1.3%, 84.6  3.7%, and 80.8  4.4%
in Group B. Although survival overlaps in the first 4 years
(Fig. 3b), thereafter the survival falls in Group A, the differ-
ence being at the limit of statistical significance (P = 0.066).
Survival free from serious infections at 1, 5, and 8 years
was, respectively, 74.0  6.8%, 58.5  8.2%, and
54.6  8.5% in Group A and 85.4  2.9%, 72.1  4.1%,
and 68.7  4.5% for Group B. Hence, there is a decrease in
survival free from serious infections in the sex mismatched
group, in the threshold of statistical significance
(P = 0.076; Fig. 3c).
Discussion
The results of cardiac transplantation are influenced by
multiple donor factors [2]. The mismatch of sex as an
adverse factor has not been consensual. Initially, female
donors were thought to be responsible for decreased
survival, irrespective of the recipient gender [3]. However,
the fact that the majority of recipients are male could hide
the mismatch of gender as a risk factor. Indeed, while some
groups have found no differences in late mortality
[4,11,12], others have identified female donors as a risk fac-
tor only to male recipients [13–15]. Weiss et al. [16] using
the registry of the United Network for Organ Sharing
(UNOS) containing data on 18 240 patients, pointed in
this direction. However, more recently, Khush et al. [5]
analyzed the registry of the ISHLT with 60 584 recipients
and concluded that sex mismatch reduces survival in
both male and female recipients. Although these large
multicenter experiences have a clear statistical advantage,
they have the disadvantage of different approaches to the
selection of both donors and recipients. Here, we believe,
lies an advantage of our study.
In our country, we are blessed by a legal presumed donor
consent, which allowed us to have short wait-list times, low
average donor age, and, related to a relatively small
geographic area, low ischemic times. The quality of the
donors partially explains the good overall results. But even
in this good ground, we believe that if a difference exists in
the behavior of the female donors on male receptors, it
should be apparent.
Even if some results in the literature indicate that the sex
mismatch may result in decreased survival, the progressive
reduction of donor availability legitimizes its use, especially
in confront with the mortality of patients in the waiting list.
Hence, we have never rejected an, otherwise suitable,
female donor. We intended to study only the effect of the
female donor to male recipient, which appears to be the
mismatch with most important consequences. We believe
that our series also has the advantage of being recent, con-
trasting with the results of other series of patients with
important historical components, which may no longer be
translated to real life.
(a) (b) (c)
Figure 3 (a) Survival free from cardiac allograft vasculopathy; (b) survival free from malignancy; and (c) survival free from serious infections.
© 2014 Steunstichting ESOT 27 (2014) 1303–1310 1307
Correia et al. Gender mismatch in cardiac transplantation
One of the possible reasons that have been identified for
worse outcomes of female donors to male recipients is the
disparity in the size of the heart itself, usually smaller in the
female gender. In this series, the two groups of recipients,
with and without mismatch, were quite homogeneous,
including for the immunosuppressive regimen, but for two
significant differences: BMI and transpulmonary gradient/
sPAP. This results from the fact that we tended to choose
smaller male recipients, with less pulmonary hypertension,
to receive hearts from female donors.
Due to denervation, the transplanted heart usually shows
chronotropic incompetence and diastolic dysfunction. As
such, the increase in cardiac output depends primarily on
the increase in stroke volume at the expense of increased
filling pressures [17,18]. Small hearts have lower reserves
and greater difficulty to adapt to the new situation. If we
add to these conditions an increase in right ventricular
afterload, cardiac output may be compromised. Recently,
Reed et al. [18] have shown, through the analysis of 31 634
patients of the UNOS registry, that the difference in mor-
tality in male recipients with sex mismatch disappeared
when adjusted to the predicted size of the heart.
Our results are in line with these. We registered only a
few cases of donor/recipient weight ratio <0.8. These facts
partially explain the good behavior of our transplanted
patients with gender mismatch, overlapping those of the
group with male donors. Overall survival after 8 years was
very similar between the two groups (66.6  8.3% vs.
71.6  4.9%; P = 0.529) and slightly better than those of
the more recent (2002–2005 and 2006–2011) records of the
ISHLT [2]. Yet, in Group A, prolonged inotropic
support (>48 h) was required two times more frequently
than in Group B, revealing some degree of perioperative
dysfunction.
On a different note, the increased mortality in patients
with gender mismatch has been touted by some to be the
consequence of an increase in the number of acute cellular
rejection episodes [12,13]. However, the larger multicen-
tric series did not find an association between sex mis-
match and the incidence of acute rejection [5,18], but
these large registries have the limitations of lack of homo-
geneity caused by significant differences in the definition
and registration from center to center. In the present
study, acute cellular rejection was always defined accord-
ing to the ISHLT 2005 classification [8]. In our experience,
the incidence of acute rejection grade ≥2R in the first year
was 20.5% and 14.7%, respectively, for groups A and B.
These values are similar to or lower than those interna-
tionally reported [2]. The incidence of milder degrees of
rejection (1R), not undergoing treatment, was also mar-
ginally higher in Group A (40.9% vs. 31.4% in the first
3 months). Although these differences did not reach statis-
tical significance, it is doubtful whether this would have
happened if the series were larger. The same goes for sur-
vival free from acute rejection.
An increased incidence of vascular graft disease in male
recipients with gender mismatch has been documented in
some works [19,20]. Among possible reasons for this are
the hemodynamic stress in smaller caliber coronary arteries
[21] and the increased immune response in the female
donor heart [19]. Our series does not confirm these find-
ings. Indeed, survival free from graft vascular disease
appears better in the recipients from female donors,
although statistical significance was not reached. This find-
ing has been described before [5,22] and among the specu-
lative reasons given is the higher prevalence of coronary
artery disease in male donors, which could progress as vas-
cular disease of the graft [23].
By contrast, the group with gender mismatch had a
lower survival free from malignancy, another late-appear-
ing factor of morbidity, in the threshold of statistical signif-
icance. Although only malignant cases are considered, the
spectrum includes rapidly progressive variants and more
indolent forms. Reasons for these results, as the need for
more aggressive immunosuppression in female donors, and
hormonal and/or immune factors, are also speculative.
Although the present study does not allow us to infer about
the cause, to the best of our knowledge, this is the first time
that the association between gender mismatch and differ-
ences in the incidence of cancer is reported.
Finally, survival free from severe infection requiring hos-
pitalization for intravenous therapy was lower in Group A,
also in the threshold of statistical significance. Looking at
the literature on the subject, we found series that, despite
reporting significant differences in the incidence of acute
cellular rejection associated to sex mismatch, showed simi-
lar incidence of infections [12]. Analyzing the curve of
Fig. 3c, we find that the difference is mainly in the first
months post-transplant. Still, we believe that this might be
associated with a higher, yet nonsignificant, incidence of
acute rejection episodes grade 1R in the first 3 months,
besides grade 2R and 3R occurrences. If the relationship
between treatment with high-dose corticosteroids in the
latter and a higher incidence of infection seems likely, in
the case of grade 1R episodes, it may be associated with a
trend to higher levels of immunosuppression deliberately
used in mismatch cases, which may be important to
correct.
Study limitations
This study presents the obvious advantage of originating
from a single center, with uniform use of selection criteria
for donors and recipients, and surgical and medical
therapeutic approaches, and standardized follow-up. And,
unlike large multicenter series, the fact that our data are
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collected from a single institution allowed us not to have
significant missing data on most variables. However, the
relatively small numbers do not allow us to perform a sta-
tistical matching analysis that could make the results more
powerful. But we have tried to interpret the results in view
of these limitations throughout the text. Finally, other rea-
sons for differences in mortality in patients with donor sex
mismatch which have been identified or suggested, such as
genetic, hormonal, or immunologic factors [24,25], have
not been studied in this work.
Conclusions
The allocation of hearts from female donors to male recipi-
ents can be safely done, at least in the case of recipients
without pulmonary hypertension and when a standard
weight ratio between donor and recipient is ensured. Dur-
ing follow-up, there was no significant association of gen-
der mismatch with global survival and survival free from
acute cellular rejection and graft vascular disease, although
these patients showed a greater tendency to suffer from
infections and malignancies.
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